Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

We are very pleased to announce that Canadian Cancer Trials Group CE.6 (EORTC 26062-22061) -- A Randomized Phase III Study of Temozolomide and Short-Course Radiation vs. Short-Course Radiation Alone in the Treatment of Newly-Diagnosed Glioblastoma Multiforme (GBM) in Elderly Patients -- has reached its targeted accrual of 560 patients and was closed to accrual on October 1, 2013.

The objective of this international intergroup trial is to compare the overall survival rates between short-course radiation therapy alone and short-course radiation therapy given together with temozolomide in newly-diagnosed patients with GBM who are older than 65 years of age and are not fit for standard treatment.

The trial, led by the European Organization for Research and Treatment of Cancer (EORTC) included participation of the Canadian Cancer Trials Group, the Trans-Tasman Radiation Oncology Group (TROG) in Australia, and Japan. An international and intergroup collaboration was essential in meeting the accrual target for this rare cancer and in an elderly population. Among the 562 randomized patients, 249 patients were recruited by the EORTC, 199 patients by the Canadian Cancer Trials Group, 97 patients by TROG, and 17 patients from Japan.

You can read more about this trial on the EORTC website who have issued a release about this successful collaboration. Please use this link ...

We would like to express our thanks and appreciation to all participating centres, investigators, staff and patients who contributed to the success of the trial.